The secretary of the board of directors of Norte Bio replied: The American Insett company is a customer of the company

On January 20, 2010, 688076 responded to investors' concerns.

Investor: Hello Secretary of the Board, after a detailed study of your company's prospectus, please ask, whether the following is true, thank you: 1, the United States Inset Company is a company customer. 2, the company's pharmaceutical intermediate products downstream can be used for baletinib. Thank you very much, the secretary of the board of directors is hard

Secretary of the Board of Directors of Norte Bio: Dear investors, hello. 1. Insset Corporation is a company customer. 2. The company's APC037, APC039 downstream products are detailed in the "main products and services" in section 6 of the prospectus for the initial public offering of shares and listing on the Science and Technology Innovation Board of Nuotai Bio, Part I of the issuer's main business, main products and changes since its establishment. Thank you for your interest!

Investors: WHO recently issued an announcement recommending the combination of baricitinib and cortisol to treat patients with severe COVID-19. There is evidence that it can improve patient survival and reduce the need for ventilators. Can the advanced pharmaceutical intermediates produced by your company be used in the production of baletinib?

Secretary of the Board of Directors of Norte Bio: Dear investors, hello. The company's APC037, APC039 downstream products are detailed in the "main products and services" in section 6 of the prospectus for the initial public offering of shares and listing on the Science and Technology Innovation Board of Nuotai Bio, part I of the issuer's main business, main products and changes since its establishment. Thank you for your interest!

Investors: WHO has issued an announcement recommending the use of baritini for the treatment of severe covid-19 patients. As a supplier of intermediate medicines, does this incident have a greater positive impact on the company?

Secretary of the Board of Directors of Norte Bio: Dear investors, hello. At present, the company is not affected by the incident. Thank you for your interest!

According to the third quarter report of Nuotai Bio in 2021, the company's main revenue was 450 million yuan, up 20.05% year-on-year; the net profit attributable to the mother was 88.5825 million yuan, up 5.59% year-on-year; the deduction of non-net profit was 65.162 million yuan, up 13.02% year-on-year; among them, in the third quarter of 2021, the company's single-quarter main revenue was 141 million yuan, down 11.09% year-on-year; the single-quarter net profit attributable to the mother was 37.1645 million yuan, up 4.67% year-on-year. In a single quarter, the non-net profit was 18.3597 million yuan, down 30.8% year-on-year; the debt ratio was 11.91%, the investment income was 1.7903 million yuan, the financial expense was 5.6834 million yuan, and the gross profit margin was 56.43%.

In the past 90 days, a total of 5 institutions have given ratings, 4 buy ratings and 1 overweight rating; the target average price of institutions in the past 90 days has been 74.73; the net outflow of financing in the past 3 months has been 47.9567 million, and the balance of financing has decreased; the net outflow of margin is 10.5751 million, and the balance of margin has decreased. The Securities Star Valuation Analysis Tool shows that 688076) good company rating is 3 stars, good price rating is 1 star, and valuation comprehensive rating is 2 stars. (Rating Range: 1 ~ 5 stars, maximum 5 stars)

The main business of Nuotai Bio: customized product business and independent product selection business, of which customized product business includes CDMO business, CMO business and CRO business; Independent selection of products refers to the company around the treatment direction of diabetes, cardiovascular diseases, tumors and other diseases, with peptide drugs as the mainstay, supplemented by small molecule chemical drugs, independent selection of generic drugs with high technical barriers and good market prospects, and actively organize research and development, production, registration declaration and sales.

The chairman of the company is Zhao Deyi. Zhao Deyi, male, born in June 1963, Chinese nationality, no right of permanent residence abroad, graduated from Dalian University of Technology, college degree. Engaged in technical management in Zhuji Industrial Equipment Installation Company; From December 2003 to May 2019, he served as an executive director of Zhongyi Group; In September 2004, it invested in Hangzhou Nuotai Pharmaceutical Technology Co., Ltd. (transferred, now renamed Hangzhou Arnold Biomedical Technology Co., Ltd.) and began to get involved in the field of peptide drugs; Since April 2009, he has served as a director of the company. Since the company's overall change to a joint-stock company, he has served as the chairman of the board of directors of the company.

This article is compiled by the Securities Star Data Center based on publicly available data and does not constitute investment opinions or suggestions, if you have any questions, please contact us.